Library Posts Archive | Page 6 of 14

What Is an IPR and How Can It Help Your Business?

breakdance January 14, 2022 No Comments

An Inter Partes Review (IPR) is a relatively new administrative proceeding for patents. The IPR is conducted before the Patent Trial and Appeal Board (PTAB) of the United States Patent…

Hoffmann & Baron Prevails Before The Federal Circuit On Behalf Of Aquestive Therapeutics, Inc.

breakdance October 19, 2021 No Comments

Neurelis, Inc.’s US Patent No. 9,763,876 (“the ‘876 patent”) is listed in the FDA’s “Orange Book” under Neurelis’ Valtoco® product (diazepam nasal spray). Neurelis had appealed the PTAB’s August 6,…

Hoffmann & Baron LLP Welcomes Joseph W. Ricigliano, JD, Ph.D.

breakdance June 16, 2021 No Comments

Hoffmann & Baron, LLP is pleased to announce that Joseph W. Ricigliano, JD, Ph.D., has joined the firm as a Partner on June 14, 2021; Joe will be responsible for…

U.S. Supreme Court Denies BDSI’s Petition for Certiorari Seeking to Require the U.S. PTAB to Reconsider Decision to Not Institute Inter Partes Reviews of Aquestive’s U.S. Patent No. 8,765,167, as Drafted/Prosecuted/Defended By Hoffmann & Baron

breakdance October 14, 2020 No Comments

Aquestive Therapeutics, Inc.’s U.S. Patent No. 8,765,167 (“Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions”) is a cornerstone of Aquestive’s PharmFilm® rapidly-dissolving, thin-film pharmaceutical technology; the ‘167 Patent was…

PTAB Confirms Hoffmann & Baron’s Successful Invalidation of All Claims of US Patent No. 9,320,765 on behalf of Rimfrost AS (Rimfrost AS v. Aker Biomarine AS)

breakdance October 6, 2020 No Comments

Aker Biomarine AS owns U.S. Patent No. 9,320,765 (“the ‘765 patent”), titled “Bioeffective Krill Oil Compositions.” On December 15, 2017, Rimfrost AS, through its counsel Hoffmann & Baron, petitioned the…

Hoffmann & Baron, on Behalf of Aquestive, Inc., Successfully Invalidates All Claims of Orange Book Patent for Valtoco® Nasal Spray in Aquestive Therapeutics, Inc. v. Neurelis, Inc.

breakdance September 16, 2020 No Comments

Neurelis, Inc. is the owner of US Patent No. 9,763,876 (“the ‘876 patent”), which is listed in the FDA’s “Orange Book” under Neurelis’ Valtoco® product (diazepam nasal spray). On January…

Hoffmann & Baron LLP Offices Open

breakdance June 19, 2020 No Comments

Hoffmann & Baron LLP offices are open for normal business hours in accordance with state and CDC guidelines.

Hoffmann & Baron LLP COVID-19 Update & Protocol

breakdance March 12, 2020 No Comments

Hoffmann & Baron LLP offices remain open for business in order to properly serve our clients. Our attorneys and staff are working remotely from home, and we have curtailed unnecessary…

John Gallagher Featured in Long Island Business News

breakdance February 11, 2020 No Comments

John Gallagher was featured by Long Island Business News in its annual section entitled “Who’s Who in Intellectual Property Law.” View LIBN “Who’s Who in Intellectual Property Law” – John…

Hoffmann & Baron’s Defense of Rimfrost Analyzed on Lexology

breakdance February 11, 2020 No Comments

Hoffmann & Baron has successfully invalidated several patents, asserted against its client, Rimfrost AS, in inter partes review (IPR) proceedings before the Patent Trial and Board (PTAB). As detailed in…

Archives: Library Posts

What Is an IPR and How Can It Help Your Business?

Hoffmann & Baron Prevails Before The Federal Circuit On Behalf Of Aquestive Therapeutics, Inc.

Hoffmann & Baron LLP Welcomes Joseph W. Ricigliano, JD, Ph.D.

U.S. Supreme Court Denies BDSI’s Petition for Certiorari Seeking to Require the U.S. PTAB to Reconsider Decision to Not Institute Inter Partes Reviews of Aquestive’s U.S. Patent No. 8,765,167, as Drafted/Prosecuted/Defended By Hoffmann & Baron

PTAB Confirms Hoffmann & Baron’s Successful Invalidation of All Claims of US Patent No. 9,320,765 on behalf of Rimfrost AS (Rimfrost AS v. Aker Biomarine AS)

Hoffmann & Baron, on Behalf of Aquestive, Inc., Successfully Invalidates All Claims of Orange Book Patent for Valtoco® Nasal Spray in Aquestive Therapeutics, Inc. v. Neurelis, Inc.

Hoffmann & Baron LLP Offices Open

Hoffmann & Baron LLP COVID-19 Update & Protocol

John Gallagher Featured in Long Island Business News

Hoffmann & Baron’s Defense of Rimfrost Analyzed on Lexology

OFFICES